US health officials have tried to downplay concerns that the country could now be prepared for flu swine pandemic coming this fall. Vaccine producers have difficulty to produce large quantities of vaccine, and some experts predict other countries where the vaccine is produced may hoard. But on a conference call today, the specialist flu Anne Schuchat of the Centers for Disease Control and Prevention in Atlanta said she did not care.
Last week, the World Health Organization reported that vaccine manufacturers have received the pandemic vaccine yields that are 50% to 75% lower than those of vaccines against seasonal influenza. They will try to improve it with new vaccine strains, but even if they fail, the planning for a pandemic US incorporated these setbacks, Schuchat told reporters. "For our planning assumptions, we are really on the right track and does not care to meet expectations," she said.
Today, a story from the Associated Press was also suggested, as others before herself that vaccine contracts might be worthless if the country where the vaccine is produced put of first, their own people and stop the product being exported. (Most vaccines under contract by the United States is produced in Europe.) But Schuchat said that "the concerns that have been raised in the media were not part of the dialogue" with manufacturers. "We have not got information that makes us question the offer we have promised. "
Plans are taking shape for a test program developed new vaccines against H1N1 influenza in the United States, funded in part by the National Institutes of Health and conducted at the Vaccine and Treatment Units assessment, a network of clinical centers across the country. "Manufacturers and NIH have worked together to plan the studies," chief scientist Jesse Goodman of the Food and Drug Administration said at the briefing today. "We will integrate them into a whole program that we . can answer as many questions as we can "the plans will be discussed on July 23 at a meeting of the Advisory Committee on Vaccines and FDA organic Related products" We expect the first trials to begin shortly, "said Goodman.
the studies will also test vaccines with adjuvants. further, known oil adjuvants in water might make them more potent vaccines and can stretch the limited supply of vaccines, but the compounds already in use in Europe, has not received FDA approval. the US could continue to use them, Schuchat said, probably by a so-called emergency use authorization instead of the way of the authorization to exercise normal. But it will only do so if studies show adjuvants to be "clearly beneficial and necessary," said Goodman. Bruce Gellin, director of the National Vaccine Program Office, said he has "high expectations" that the shooting function without adjuvant, the vaccine against seasonal flu are.
Which groups should be targeted for the vaccine, which should be first in line if the offer does not respond, will be discussed on July 29 at a special meeting of the Advisory Committee on Immunization Practices Atlanta.
0 Komentar